← Back to Investor Relations
In the Press
Quest Diagnostics to Offer Helio Genomics' AI-Powered Liver Cancer Blood Test Across US Network
Why This Matters
Dealroom.co is a leading platform for venture capital intelligence and startup tracking used by investors across Europe and globally. Coverage here puts Helio Genomics on the radar of VCs and innovation scouts evaluating the AI diagnostics space.
Article Summary
Dealroom.co reports that Helio Genomics has partnered with Quest Diagnostics to make HelioLiver widely available across the US starting April 2026. The article highlights that the test offers superior sensitivity to ultrasound for early-stage detection in high-risk individuals with cirrhosis or hepatitis B, noting that liver cancer incidence has tripled since 1980 while 80–90% of eligible adults skip recommended ultrasounds. Testing continues at Helio's West Lafayette laboratory.